Index RUT
P/E -
EPS (ttm) -2.64
Insider Own 9.55%
Shs Outstand 127.46M
Perf Week -7.47%
Market Cap 970.33M
Forward P/E -
EPS next Y -2.85
Insider Trans -0.79%
Shs Float 120.03M
Perf Month 7.58%
Income -329.12M
PEG -
EPS next Q -0.73
Inst Own 72.53%
Short Float 8.00%
Perf Quarter -8.05%
Sales 35.33M
P/S 27.46
EPS this Y -1.28%
Inst Trans 1.45%
Short Ratio 7.24
Perf Half Y -27.48%
Book/sh 5.64
P/B 1.30
EPS next Y -0.69%
ROA -35.03%
Short Interest 9.60M
Perf Year -38.88%
Cash/sh 5.65
P/C 1.29
EPS next 5Y -
ROE -40.40%
52W Range 5.70 - 13.32
Perf YTD -33.61%
Dividend Est. -
P/FCF -
EPS past 5Y -38.74%
ROI -41.51%
52W High -45.12%
Beta 1.69
Dividend TTM -
Quick Ratio 20.73
Sales past 5Y 319.82%
Gross Margin 84.53%
52W Low 28.25%
ATR (14) 0.59
Dividend Ex-Date -
Current Ratio 20.73
EPS Y/Y TTM 5.78%
Oper. Margin -1045.73%
RSI (14) 52.53
Volatility 7.46% 7.76%
Employees 323
Debt/Eq 0.07
Sales Y/Y TTM 2873.74%
Profit Margin -931.62%
Recom 1.09
Target Price 23.20
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q 19.93%
Payout -
Rel Volume 1.21
Prev Close 7.82
Sales Surprise 8233.33%
EPS Surprise 14.69%
Sales Q/Q 4327.88%
Earnings May 02 AMC
Avg Volume 1.33M
Price 7.31
SMA20 3.50%
SMA50 7.58%
SMA200 -14.31%
Trades
Volume 1,601,097
Change -6.58%
Date
Action
Analyst
Rating Change
Price Target Change
May-10-24 Upgrade
Barclays
Equal Weight → Overweight
$15
Apr-20-23 Upgrade
Jefferies
Underperform → Hold
$12.50
Apr-19-23 Upgrade
Raymond James
Outperform → Strong Buy
$29
Apr-13-23 Initiated
Raymond James
Outperform
$29
Feb-03-23 Initiated
Oppenheimer
Outperform
$33
Sep-30-22 Initiated
Barclays
Equal Weight
$23
Sep-02-22 Initiated
Stifel
Buy
$40
Jun-06-22 Initiated
Jefferies
Underperform
$13
Feb-01-22 Initiated
Berenberg
Buy
$45
Jul-21-21 Initiated
BofA Securities
Buy
$50
Dec-15-20 Reiterated
H.C. Wainwright
Buy
$54 → $57
Dec-08-20 Initiated
JMP Securities
Mkt Outperform
$66
Nov-05-20 Initiated
H.C. Wainwright
Buy
$54
Aug-10-20 Initiated
JP Morgan
Neutral
$36
Aug-10-20 Initiated
Guggenheim
Buy
$48
Aug-10-20 Initiated
Goldman
Buy
$64
Aug-10-20 Initiated
Cowen
Outperform
Show Previous Ratings
Jun-06-24 07:00AM
Jun-05-24 04:05PM
May-21-24 04:05PM
May-13-24 08:30AM
May-10-24 10:01AM
08:57AM
Loading…
May-06-24 08:57AM
May-02-24 09:55PM
05:55PM
05:40PM
04:05PM
Apr-25-24 04:05PM
Apr-11-24 04:05PM
Mar-17-24 05:20PM
Mar-15-24 12:39PM
Mar-13-24 09:55AM
04:05PM
Loading…
Feb-26-24 04:05PM
09:55AM
Feb-22-24 04:40PM
04:05PM
Feb-15-24 04:05PM
10:00AM
03:29AM
Feb-01-24 04:05PM
Jan-18-24 05:37AM
Jan-08-24 07:00AM
Jan-02-24 04:05PM
Nov-30-23 09:55AM
Nov-14-23 09:55AM
Nov-07-23 04:05PM
Nov-02-23 06:21PM
04:05PM
Loading…
04:05PM
Oct-31-23 12:00PM
Oct-26-23 04:05PM
10:02AM
Oct-12-23 04:05PM
Sep-18-23 04:05PM
Aug-31-23 10:16PM
Aug-08-23 06:05PM
04:02PM
Aug-01-23 04:05PM
May-25-23 05:01PM
May-24-23 04:05PM
May-18-23 08:16AM
May-04-23 07:25PM
04:05PM
Apr-27-23 04:05PM
10:03AM
Apr-21-23 02:48PM
Apr-20-23 02:20AM
Apr-19-23 07:30AM
Apr-18-23 10:40AM
Apr-14-23 05:05AM
Apr-13-23 06:12PM
03:49PM
Apr-07-23 07:44AM
Apr-06-23 09:55AM
Mar-06-23 07:30AM
Mar-01-23 07:30AM
Feb-25-23 07:31AM
Feb-23-23 05:45PM
04:05PM
Feb-21-23 10:00AM
Feb-16-23 04:05PM
10:01AM
Feb-07-23 05:01PM
Feb-02-23 07:30AM
Jan-13-23 11:11AM
Jan-03-23 07:30AM
Dec-31-22 08:53AM
Nov-24-22 08:02AM
Nov-17-22 01:58PM
Nov-07-22 07:30AM
Nov-03-22 06:35PM
04:05PM
Oct-27-22 04:05PM
Oct-14-22 10:14AM
Sep-26-22 07:30AM
Sep-23-22 07:30AM
Sep-12-22 09:30PM
07:00AM
06:30AM
Sep-11-22 09:45AM
Sep-08-22 04:06PM
10:25AM
Aug-30-22 11:15AM
Aug-25-22 02:48PM
(Investor's Business Daily)
Aug-18-22 04:05PM
Aug-04-22 04:05PM
Jul-28-22 04:05PM
Jun-27-22 06:00AM
Jun-16-22 07:30AM
May-26-22 07:30AM
May-07-22 09:59AM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-28-22 04:05PM
Feb-24-22 04:05PM
Feb-17-22 04:05PM
Feb-10-22 11:51AM
Feb-02-22 07:30AM
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rubin Jami Director Jun 10 '24 Option Exercise 5.04 42,242 212,900 67,242 Jun 12 04:06 PM Rahmer Peter See remarks Jun 05 '24 Sale 7.06 20,450 144,377 432,425 Jun 05 08:01 PM Rahmer Peter See remarks Jun 04 '24 Sale 6.64 40,595 269,551 452,875 Jun 05 08:01 PM Rahmer Peter See remarks Jun 03 '24 Sale 6.47 19,864 128,520 493,470 Jun 05 08:01 PM Bergstrom Donald A President, R&D Apr 29 '24 Sale 6.38 2,686 17,137 527,427 Apr 29 08:30 PM Catinazzo Thomas Chief Financial Officer Apr 29 '24 Sale 6.38 1,695 10,814 339,803 Apr 29 08:31 PM Adams Brian Chief Legal Officer Apr 29 '24 Sale 6.38 1,623 10,355 325,767 Apr 29 08:33 PM Rahmer Peter See remarks Apr 29 '24 Sale 6.38 1,345 8,581 513,334 Apr 29 08:36 PM Bergstrom Donald A President, R&D Mar 27 '24 Sale 7.70 765 5,890 530,113 Mar 29 04:15 PM Catinazzo Thomas Chief Financial Officer Mar 27 '24 Sale 7.70 348 2,680 341,498 Mar 29 04:15 PM Adams Brian Chief Legal Officer Mar 27 '24 Sale 7.70 348 2,680 327,390 Mar 29 04:15 PM Rahmer Peter See remarks Mar 27 '24 Sale 7.70 298 2,295 514,679 Mar 29 04:15 PM Bergstrom Donald A President, R&D Jan 29 '24 Sale 9.64 3,178 30,636 530,878 Jan 31 04:08 PM Catinazzo Thomas Chief Financial Officer Jan 29 '24 Sale 9.64 2,005 19,328 341,846 Jan 31 04:11 PM Adams Brian Chief Legal Officer Jan 29 '24 Sale 9.64 1,929 18,596 327,738 Jan 31 04:05 PM Rahmer Peter See remarks Jan 29 '24 Sale 9.64 1,651 15,916 514,977 Jan 31 04:14 PM Bergstrom Donald A President, R&D Dec 27 '23 Sale 11.51 977 11,245 234,056 Dec 29 04:17 PM Catinazzo Thomas Chief Financial Officer Dec 27 '23 Sale 11.51 294 3,384 143,851 Dec 29 04:22 PM Adams Brian Chief Legal Officer Dec 27 '23 Sale 11.51 294 3,384 129,667 Dec 29 04:14 PM Rahmer Peter See remarks Dec 27 '23 Sale 11.51 244 2,808 316,628 Dec 29 04:26 PM Bergstrom Donald A President, R&D Oct 30 '23 Sale 6.03 3,451 20,810 235,033 Nov 01 04:14 PM Catinazzo Thomas Chief Financial Officer Oct 30 '23 Sale 6.03 1,697 10,233 144,145 Nov 01 04:18 PM Adams Brian Chief Legal Officer Oct 30 '23 Sale 6.03 1,632 9,841 129,961 Nov 01 04:07 PM Rahmer Peter See remarks Oct 30 '23 Sale 6.03 1,354 8,165 316,872 Nov 01 04:21 PM Bergstrom Donald A President, R&D Sep 27 '23 Sale 8.38 648 5,430 238,484 Sep 29 04:52 PM Catinazzo Thomas Chief Financial Officer Sep 27 '23 Sale 8.38 294 2,464 145,842 Sep 29 04:22 PM Adams Brian Chief Legal Officer Sep 27 '23 Sale 8.38 294 2,464 131,593 Sep 29 04:10 PM Rahmer Peter See remarks Sep 27 '23 Sale 8.38 244 2,045 318,226 Sep 29 04:32 PM Bergstrom Donald A President, R&D Jul 28 '23 Sale 11.80 2,683 31,659 237,904 Jul 31 04:48 PM Catinazzo Thomas Chief Financial Officer Jul 28 '23 Sale 11.80 1,693 19,977 146,136 Jul 31 04:50 PM Adams Brian Chief Legal Officer Jul 28 '23 Sale 11.80 1,628 19,210 131,887 Jul 31 04:46 PM Rahmer Peter See remarks Jul 28 '23 Sale 11.80 1,352 15,954 316,808 Jul 31 04:52 PM Bergstrom Donald A President, R&D Jun 27 '23 Sale 12.12 647 7,842 240,587 Jun 28 05:06 PM Adams Brian Chief Legal Officer Jun 27 '23 Sale 12.12 294 3,563 133,515 Jun 28 05:02 PM Catinazzo Thomas Chief Financial Officer Jun 27 '23 Sale 12.12 294 3,563 147,829 Jun 28 05:08 PM Rahmer Peter See remarks Jun 27 '23 Sale 12.12 244 2,957 318,160 Jun 28 05:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite